West Pharmaceutical Services announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close in mid-2026.
West is committed to the continued commercial supply of SmartDose® 3.5mL On‑Body Delivery System along with the execution of ongoing critical project execution commitments prior to close, which includes the potential for future project payments on achievement of milestones prior to closing.
"West pioneered the innovation of the on-body delivery device technology for complex injectable medicines, which has improved the lives of people around the world," said Eric M. Green, President, Chief Executive Officer and Chair of the Board. "As part of our portfolio review, we have determined it is best to transition the SmartDose 3.5mL product to AbbVie. This decision aligns with our ongoing commitment to our customer development pipeline and patient-centric approach for large dose on-body delivery devices to drive durable and profitable growth."
SmartDose 3.5mL On-Body Delivery System revenues are anticipated to be approximately 4 percent of revenues in fiscal year 2025. The company expects to provide additional details when it gives 2026 guidance on its fourth quarter 2025 earnings call in February. West will continue to develop and manufacture all other versions of SmartDose, including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger volumes.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!